keyword
MENU ▼
Read by QxMD icon Read
search

Chlorthalidone

keyword
https://www.readbyqxmd.com/read/28259499/chlorthalidone-versus-amlodipine-for-hypertension-in-kidney%C3%A2-transplant-recipients-treated-with-tacrolimus-a%C3%A2-randomized-crossover-trial
#1
Arthur D Moes, Dennis A Hesselink, Anton H van den Meiracker, Robert Zietse, Ewout J Hoorn
BACKGROUND: Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension. Recent data indicate that calcineurin inhibitors activate the thiazide-sensitive sodium chloride cotransporter, providing further rationale to test thiazides in this population. STUDY DESIGN: Randomized noninferiority crossover trial (noninferiority margin, -2.8mmHg). SETTING & PARTICIPANTS: Hypertensive kidney transplant recipients using tacrolimus (median duration, 2...
March 1, 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/28197292/chlorthalidone-plus-amiloride-reduces-the-central-systolic-blood-pressure-in-stage-1-hypertension-patients
#2
Leticia Aparecida Barufi Fernandes, Elizabeth do Espirito Santo Cestario, Luciana Neves Cosenso-Martin, Jose Fernando Vilela-Martin, Juan Carlos Yugar-Toledo, Flavio Danni Fuchs
BACKGROUND: Hypertension reduction strategies use blood pressure in the brachial artery as the primary endpoint. Individuals who achieve the target blood pressure reduction with antihypertensive treatment have residual cardiovascular risk attributed to the difference in pressure between the aorta and brachial artery. Antihypertensive treatment affects the intrinsic properties of the vascular wall and arterial stiffness markers and consequently the central pressure. Recent publications stress the importance of adequate control of the central compared to peripheral blood pressure...
December 2016: Cardiology Research
https://www.readbyqxmd.com/read/28178366/the-simultaneous-uplc-ms-ms-determination-of-emerging-drug-combination-candesartan-and-chlorthalidone-in-human-plasma-and-its-application
#3
Bhargav Patel, Arvind G Jangid, B N Suhagia, Nirmal Desai
A novel, precise, sensitive and accurate ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method has been developed for the simultaneous determination of novel drug combination, candesartan (CAN) and chlorthalidone (CHL) in human plasma. Chromatographic separation was achieved on Waters Acquity UPLC BEH C18 (50 mm × 2.1 mm, 1.7 µm). Mobile phase consisting of 1 mM Ammonium acetate in water: acetonitrile (20:80 v/v) was used. The total chromatographic runtime was 1...
February 8, 2017: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/28115488/genome-wide-prioritization-and-transcriptomics-reveal-novel-signatures-associated-with-thiazide-diuretics-blood-pressure-response
#4
Mohamed H Shahin, Ana C Sá, Amy Webb, Yan Gong, Taimour Langaee, Caitrin W McDonough, Alberto Riva, Amber L Beitleshees, Arlene B Chapman, John G Gums, Stephen T Turner, Eric Boerwinkle, Steven E Scherer, Wolfgang Sadee, Rhonda M Cooper-DeHoff, Julie A Johnson
BACKGROUND: Thiazide diuretics are among the most commonly prescribed antihypertensives. However, <50% of thiazide-treated patients achieve blood pressure (BP) control. Herein, we used different omics (genomics and transcriptomics) to identify novel biomarkers of thiazide diuretics BP response. METHODS AND RESULTS: Genome-wide analysis included 228 white hypertensives with BP determined at baseline and after 9 weeks of hydrochlorothiazide. Single-nucleotide polymorphisms with P <5×10(-)(5) were prioritized according to their biological function, using RegulomeDB, haploreg, and Genome-Wide Annotation of Variants...
January 2017: Circulation. Cardiovascular Genetics
https://www.readbyqxmd.com/read/28106027/-all-diuretics-used-in-the-treatment-of-hypertension-are-not-the-same
#5
Serkan Asil, Enver Atalar
Diuretics have been used for years to treat hypertension as both a monotherapy and in combination. Hydrochlorothiazide, indapamide, and chlorthalidone have frequently been considered in the same category as thiazide diuretics, but there is no evidence that their activities are similar. Studies have shown that chlorthalidone and indapamide reduce cardiovascular morbidity and mortality; however, there is no study indicating that hydrochlorothiazide has beneficial effects on cardiovascular outcomes such as myocardial infarction, renal failure, stroke, or death...
January 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/27984005/treatment-resistant-hypertension-and-outcomes-based-on-randomized-treatment-group-in-allhat
#6
Sripal Bangalore, Barry R Davis, William C Cushman, Sara L Pressel, Paul M Muntner, David A Calhoun, John B Kostis, Paul K Whelton, Jeffrey L Probstfield, Mahboob Rahman, Henry R Black
BACKGROUND: Although hypertension guidelines define treatment-resistant hypertension as blood pressure uncontrolled by ≥3 antihypertensive medications, including a diuretic, it is unknown whether patient prognosis differs when a diuretic is included. METHODS: Participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) were randomly assigned to first-step therapy with chlorthalidone, amlodipine, or lisinopril. At a Year 2 follow-up visit, those with average blood pressure ≥140 mm Hg systolic or ≥90 mm Hg diastolic on ≥3 antihypertensive medications, or blood pressure <140/90 mm Hg on ≥4 antihypertensive medications were identified as having apparent treatment-resistant hypertension...
April 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/27965209/effectiveness-of-chlorthalidone-plus-amiloride-for-the-prevention-of-hypertension-the-prever-prevention-randomized-clinical-trial
#7
Sandra Costa Fuchs, Carlos E Poli-de-Figueiredo, José A Figueiredo Neto, Luiz César N Scala, Paul K Whelton, Francisca Mosele, Renato Bandeira de Mello, José F Vilela-Martin, Leila B Moreira, Hilton Chaves, Marco Mota Gomes, Marcos R de Sousa, Ricardo Pereira E Silva, Iran Castro, Evandro José Cesarino, Paulo Cesar Jardim, João Guilherme Alves, André Avelino Steffens, Andréa Araujo Brandão, Fernanda M Consolim-Colombo, Paulo Ricardo de Alencastro, Abrahão Afiune Neto, Antônio C Nóbrega, Roberto Silva Franco, Dario C Sobral Filho, Alexandro Bordignon, Fernando Nobre, Rosane Schlatter, Miguel Gus, Felipe C Fuchs, Otávio Berwanger, Flávio D Fuchs
BACKGROUND: Prehypertension is associated with higher cardiovascular risk, target organ damage, and incidence of hypertension. The Prevention of Hypertension in Patients with PreHypertension (PREVER-Prevention) trial aimed to evaluate the efficacy and safety of a low-dose diuretic for the prevention of hypertension and end-organ damage. METHODS AND RESULTS: This randomized, parallel, double-blind, placebo-controlled trial was conducted in 21 Brazilian academic medical centers...
December 13, 2016: Journal of the American Heart Association
https://www.readbyqxmd.com/read/27938852/electrocardiographic-measures-of-left-ventricular-hypertrophy-in-the-antihypertensive-and-lipid-lowering-treatment-to-prevent-heart-attack-trial
#8
Michael E Ernst, Barry R Davis, Elsayed Z Soliman, Ronald J Prineas, Peter M Okin, Alokananda Ghosh, William C Cushman, Paula T Einhorn, Suzanne Oparil, Richard H Grimm
Left ventricular hypertrophy (LVH) predicts cardiovascular risk in hypertensive patients. We analyzed baseline/follow-up electrocardiographies in 26,376 Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial participants randomized to amlodipine (A), lisinopril (L), or chlorthalidone (C). Prevalent/incident LVH was examined using continuous and categorical classifications of Cornell voltage. At 2 and 4 years, prevalence of LVH in the C group (5.57%; 6.14%) was not statistically different from A group (2 years: 5...
December 2016: Journal of the American Society of Hypertension: JASH
https://www.readbyqxmd.com/read/27893045/association-of-3-different-antihypertensive-medications-with-hip-and-pelvic-fracture-risk-in-older-adults-secondary-analysis-of-a-randomized-clinical-trial
#9
Rachel Puttnam, Barry R Davis, Sara L Pressel, Paul K Whelton, William C Cushman, Gail T Louis, Karen L Margolis, Suzanne Oparil, Jeffrey Williamson, Alokananda Ghosh, Paula T Einhorn, Joshua I Barzilay
Importance: On the basis of observational studies, the use of thiazide diuretics for the treatment of hypertension is associated with reduced fracture risk compared with nonuse. Data from randomized clinical trials are lacking. Objective: To examine whether the use of thiazide diuretics for the treatment of hypertension is associated with reduced fracture risk compared with nonuse. Design, Setting, and Participants: Using Veterans Affairs and Medicare claims data, this study examined hip and pelvic fracture hospitalizations in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial participants randomized to first-step therapy with a thiazide-type diuretic (chlorthalidone), a calcium channel blocker (amlodipine besylate), or an angiotensin-converting enzyme inhibitor (lisinopril)...
January 1, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/27798457/refractory-versus-resistant-hypertension
#10
Mohammed Siddiqui, David A Calhoun
PURPOSE OF REVIEW: Refractory hypertension is a recently proposed phenotype of antihypertensive treatment failure. As such it represents an extreme subtype of resistant or difficult-to-treat hypertension. Resistant hypertension is relatively common with an estimated prevalence of 10-20% of treated hypertensive patients. It is typically defined as having an uncontrolled blood pressure on three or more antihypertensive medications, including a diuretic. Refractory hypertension is rare with a prevalence of approximately 5% of patients with uncontrolled resistant hypertension...
January 2017: Current Opinion in Nephrology and Hypertension
https://www.readbyqxmd.com/read/27777360/trends-in-antihypertensive-medication-use-among-us-patients-with-resistant-hypertension-2008-to-2014
#11
Andrew Y Hwang, Chintan Dave, Steven M Smith
Little is known of US trends in antihypertensive drug use for patients with treatment-resistant hypertension (TRH). We analyzed antihypertensive use among patients with TRH (treated with ≥4 antihypertensive drugs concurrently) from July 2008 through December 2014 using Marketscan administrative data. We included adults aged 18 to 65 years, with ≥6 months of continuous enrollment, a hypertension diagnosis, and ≥1 episode of overlapping use of ≥4 antihypertensive drugs; patients with heart failure were excluded...
December 2016: Hypertension
https://www.readbyqxmd.com/read/27773415/diuretics-in-primary-hypertension-reloaded
#12
EDITORIAL
Sundeep Mishra
Diuretics have long been cherished as drugs of choice for uncomplicated primary hypertension. Robust mortality and morbidity data is available for diuretics to back this strategy. Off-late the interest for diuretics has waned off perhaps due to availability of more effective drugs but more likely due to perceived lack of tolerance and side-effect profile of high-dose of diuretics required for mortality benefit. Low-dose diuretics particularly thiazide diuretics are safer but lack the mortality benefit shown by high-dose...
September 2016: Indian Heart Journal
https://www.readbyqxmd.com/read/27753981/pl-02-3-management-of-elderly-hypertension-whom-to-treat-and-how-low-to-go
#13
Michael Weber
Age is the most powerful cardiovascular risk factor. Based on a meta-analysis of a million control patients in hypertension trials, the Clinical Trialists Collaboration has estimated that doubling of major cardiac and stroke events occurs with age increments of < 10 years (1). Data from the ACCOMPLISH trial, which will be presented at this ISH meeting for the first time, show that patients aged > 70 (mean: 75.2), compared with those < 70 (mean: 63.7), had a 2.82-fold greater event rate for cardiovascular death and a 2...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27753872/ish-aha-1-a-case-of-refractory-hypertension-controlled-by-repeated-renal-denervation-and-celiac-plexus-block-a-case-of-refractory-sympathetic-overload
#14
Chan Joo Lee, Yeongmin Woo, Byeong-Keuk Kim, Kyung Bong Yoon, Hae-Young Lee, Sungha Park
A 30-year-old woman was referred to our hospital due to high blood pressure, dizziness, headache and blurred vision. She had past history of preeclampsia and gestational hypertension 4 years ago but she had not taken antihypertensive medication in spite of remained hypertension after delivery. She was hospitalized for fever due to urinary tract infection and severe hypertension which was above 210/140 mmHg. Despite maximal medical treatment with telmisartan 80 mg, nifedipine 120 mg, carvedilol 50 mg, doxazocin 8 mg, chlorthalidone 50 mg, spironolactone 50 mg#2, isosorbide dinitrate 80 mg and intermittent intravenous administration of nicardipine and labetalol, her systolic blood pressure remained above 160 mmHg and repeatedly measured above 200 mmHg...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27727743/comparative-antihypertensive-effect-of-hydrochlorothiazide-and-chlorthalidone-on-essential-hypertension-jnc-vii-stage-i
#15
Sanjeev Kumar, Gurleen Chahal, Savita Kapila, Ashish Kumar
No abstract text is available yet for this article.
January 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27721529/did-all-thiazides-take-undue-credit-of-good-work-of-chlorthalidone
#16
EDITORIAL
Kamal H Sharma
No abstract text is available yet for this article.
September 2016: Indian Journal of Pharmacology
https://www.readbyqxmd.com/read/27643109/ish-aha-1-a-case-of-refractory-hypertension-controlled-by-repeated-renal-denervation-and-celiac-plexus-block-a-case-of-refractory-sympathetic-overload
#17
Chan Joo Lee, Yeongmin Woo, Byeong-Keuk Kim, Kyung Bong Yoon, Hae-Young Lee, Sungha Park
A 30-year-old woman was referred to our hospital due to high blood pressure, dizziness, headache and blurred vision. She had past history of preeclampsia and gestational hypertension 4 years ago but she had not taken antihypertensive medication in spite of remained hypertension after delivery. She was hospitalized for fever due to urinary tract infection and severe hypertension which was above 210/140 mmHg. Despite maximal medical treatment with telmisartan 80 mg, nifedipine 120 mg, carvedilol 50 mg, doxazocin 8 mg, chlorthalidone 50 mg, spironolactone 50 mg#2, isosorbide dinitrate 80 mg and intermittent intravenous administration of nicardipine and labetalol, her systolic blood pressure remained above 160 mmHg and repeatedly measured above 200 mmHg...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27642892/pl-02-3-management-of-elderly-hypertension-whom-to-treat-and-how-low-to-go
#18
Michael Weber
UNLABELLED: Age is the most powerful cardiovascular risk factor. Based on a meta-analysis of a million control patients in hypertension trials, the Clinical Trialists Collaboration has estimated that doubling of major cardiac and stroke events occurs with age increments of < 10 years (1). Data from the ACCOMPLISH trial, which will be presented at this ISH meeting for the first time, show that patients aged > 70 (mean: 75.2), compared with those < 70 (mean: 63.7), had a 2...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27538129/chlorthalidone-versus-hydrochlorothiazide-a-new-kind-of-veterans-affairs-cooperative-study
#19
Frank A Lederle, William C Cushman, Ryan E Ferguson, Mary T Brophy, Louis D Fiore
No abstract text is available yet for this article.
August 16, 2016: Annals of Internal Medicine
https://www.readbyqxmd.com/read/27514506/effects-of-food-intake-on-the-pharmacokinetics-of-azilsartan-medoxomil-and-chlorthalidone-alone-and-in-fixed-dose-combination-in-healthy-adults
#20
Caroline Dudkowski, Aziz Karim, Melvin Munsaka
Azilsartan medoxomil is a long-acting angiotensin II receptor blocker used to treat hypertension as monotherapy or in fixed-dose combination (FDC) with chlorthalidone. This study assessed the effects of food intake on the plasma pharmacokinetics of the active moiety, azilsartan, and of chlorthalidone when administered as separate tablets or in FDC. Cohort 1 (n = 24) received azilsartan medoxomil (80 mg) and chlorthalidone (25 mg) once in a fasted condition and once 30 minutes after the initiation of a high-fat meal (fed)...
September 2016: Clinical Pharmacology in Drug Development
keyword
keyword
13168
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"